BioNTech (BNTX)
(Delayed Data from NSDQ)
$92.72 USD
+0.48 (0.52%)
Updated May 3, 2024 04:00 PM ET
After-Market: $93.19 +0.47 (0.51%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$92.72 USD
+0.48 (0.52%)
Updated May 3, 2024 04:00 PM ET
After-Market: $93.19 +0.47 (0.51%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Race for Coronavirus Vaccine Heats Up: Biotech ETFs to Gain
by Sweta Killa
The COVID-19 pandemic has kept biotech players all over the world on their toes for a vaccine. This new opportunity has made the sector the most attractive one to investors.
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Moderna, Pfizer, BioNTech, Sanofi and GlaxoSmithKline
Coronavirus Vaccine Race Pushes Up Pharma Giants' Production
by Ritujay Ghosh
Biotech companies and drugmakers are speeding up development of a vaccine for COVID-19. This has seen many big players joining forces to come up with a treatment.
Moderna Declines on Skepticism on Coronavirus Vaccine Data
by Zacks Equity Research
Moderna (MRNA) shares decline following a report raising questions on clinical data announced earlier this week related to its coronavirus vaccine.
5 Biotech Stocks in Focus as Race for Coronavirus Vaccine Heats Up
by Ritujay Ghosh
Drugmakers and biotech companies are initiating development of drugs, vaccines and therapies for COVID-19 and substantial progress has been made over the past month.
Biotech Companies Lead Search for Coronavirus Vaccine: 4 Winners
by Zacks.com
Although a vaccine is yet to be developed, many companies have already started ramping up manufacturing process of the experimental vaccine candidates they are working on.
Stock Market News for May 6, 2020
by Zacks Equity Research
Benchmarks ended higher on Tuesday after healthcare stocks jumped on reports of progress in coronavirus vaccine.
Coronavirus Vaccine Efforts to Aid Moderna (MRNA) Q1 Earnings?
by Zacks Equity Research
Moderna (MRNA) is progressing with coronavirus vaccine development. While grants for development are expected to have aided revenues, increased clinical activity is expected to have increased expenses.
Remdesivir Progresses on Coronavirus Trial: Pharma Upbeat
by Ritujay Ghosh
A large number of biotech companies have been working on developing drugs and vaccine for the novel coronavirus that has infected more than 3,100,000 and claimed 227,000 lives.
Pfizer/BioNTech to Begin Coronavirus Vaccine Study in Germany
by Zacks Equity Research
Pfizer (PFE) and BioNTech receive approval from regulatory authority in Germany to start an early-stage clinical study to evaluate their mRNA-based vaccine candidates for COVID-19.
Coronavirus Makes Biotech ETFs Red Hot
by Sweta Killa
The biotech space of the broader healthcare sector is currently the hottest of all segments buoyed by the COVID-19 pandemic.
BioNTech (BNTX) Soars: Stock Adds 5.2% in Session
by Zacks Equity Research
BioNTech (BNTX) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
Pfizer (PFE) Progressing Well With its Coronavirus Program
by Zacks Equity Research
Pfizer (PFE) is developing a vaccine as well as other treatment options targeting coronavirus infection, COVID-19. However, all developments are in pre-clinical stages.
Has BioNTech SE Sponsored (BNTX) Outpaced Other Medical Stocks This Year?
by Zacks Equity Research
Is (BNTX) Outperforming Other Medical Stocks This Year?
Biotech Stock Roundup: MRNA & REGN Gain on Coronavirus Treatment Updates & More
by Zacks Equity Research
The biotech sector is in focus with pipeline updates from companies evaluating treatments for the novel COVID-19.
Pfizer, Regeneron Give Update on Coronavirus Drug Development
by Kinjel Shah
Pfizer (PFE) to jointly develop BioNTech's potential coronavirus vaccine. Regeneron (REGN) could start clinical studies of a COVID-19 therapy by this summer.
Company News for Mar 18, 2020
by Zacks Equity Research
Companies In The News Are: PFE, BNTX, REGN, DNKN. TMO.
Moderna Up as First Human Trial of Coronavirus Vaccine Begins
by Zacks Equity Research
Moderna (MRNA) announces dosing of first human in a phase I clinical study evaluating its coronavirus vaccine candidate. The National Institutes of Health is conducting the study.
Company News for Mar 17, 2020
by Zacks Equity Research
Companies In The News Are: BNTX, MRNA, UAL, AAL.
Biotech Stock Roundup: Updates From HZNP & CLVS, BioNTech to Acquire Neon
by Zacks Equity Research
A low-key week for the biotech sector with a few pipeline and regulatory updates.